On the afternoon of February 19, the joint prevention and control mechanism of the State Council held a press conference. At the meeting, Mi Feng, spokesman for the National Health Commission, said that in the past week, the new confirmed cases in neighboring countries and regions have continued to grow rapidly, and the pressure on the mainland's "foreign defense import" has continued to increase.
At present, local clusters of epidemics are still occurring, and the risk of spreading the epidemic continues with the return of the holiday and the resumption of work and production. We must always adhere to the general strategy of "external prevention of import, internal prevention of rebound" and the general policy of "dynamic zeroing", overcome the paralyzing thinking, slack mentality, and accurately do a good job in epidemic prevention and control.
The press conference disclosed that recently, with the approval of the joint prevention and control mechanism of the State Council, the National Health Commission has begun to deploy a sequential strengthening of immunization.
"Talk about the local epidemic situation"
Joint Prevention and Control Working Group of the State Council
Went to Liaoning, Guangdong and Inner Mongolia
At the meeting, it was introduced that the comprehensive group of the joint prevention and control mechanism of the State Council sent a working group to jointly deal with the cluster epidemic situation in Liaoning, Inner Mongolia, Guangdong and other places.
At present, the overall situation of the epidemic situation on the mainland has remained stable.
The epidemic situation in Guangxi Baise is in the stage of closing and clearing;
The new cases of the epidemic in Huludao, Liaoning Province, have been found mainly through centralized isolation and screening, the epidemic trend is good, and the risk of social transmission has been basically controlled;
At present, the epidemic situation in Heihe, Heilongjiang is mainly concentrated in Heihe City, there are multiple transmission chains, and further flow tracing and case investigation are being carried out in an orderly manner;
Guangdong Shenzhen, Zhuhai, Dongguan recently found a cluster of epidemics caused by overseas imports, Shenzhen Aomi Kerong related epidemic situation has been basically controlled, Dongguan Zhuhai epidemic is strengthening the flow of traceability work, to prevent the risk of spread of the epidemic;
In Wenshan, Yunnan, the source of the infection is still unknown, and the local government is making every effort to accelerate the screening of nucleic acids in key areas, accelerate the screening of risk personnel, and prevent the spread of the epidemic from border areas to the inland;
The genetic sequencing results of the epidemic in Suzhou, Jiangsu Province, are the Aomi Kerong mutant strain, which is a local epidemic caused by a new overseas import source, which is still in a rapid development stage. The local government is speeding up the work of tracing the source of circulation, expanding nucleic acid screening in risk areas, strengthening the investigation of personnel in key places, and preventing the further spread of the epidemic.
The genetic sequencing results of the epidemic in Hohhot, Inner Mongolia, are Delta variants, and a local epidemic caused by a new source of import has spread to Baotou City in Inner Mongolia. At present, the epidemic is in an early stage, the number of cases is growing rapidly, and there is a cluster of epidemics in crowded places such as units and wedding banquets, and there is a high risk of community transmission and spillover.
Talk about strengthening needle vaccination
The mainland is already in key areas
Start the sequential booster immunization first
Wu Liangyou, deputy director of the Disease Control Bureau of the National Health Commission, said that recently, with the approval of the joint prevention and control mechanism of the State Council, the National Health Commission has begun to deploy a sequential strengthening of immunization.
Previously, the target population over the age of 18 who had been vaccinated with Sinopharm Zhongsheng Beijing Company, Beijing Kexing Company, Sinopharm Zhongsheng Wuhan Company inactivated vaccine or Tianjin CanSino Company's adenovirus vector vaccine for 6 months could be subjected to a dose of homologous enhanced immunization, that is, strengthened with the original vaccine.
After the implementation of the sequential enhanced immunization strategy, the target population who has completed the full vaccination of the above three inactivated vaccines can also choose the recombinant protein vaccine of Zhifeilong Koma or the adenovirus vector vaccine of Cansino for sequential enhanced immunization. For the target population, homologous booster immunization and sequential booster immunization can be selected.
In addition, the joint prevention and control mechanism of the State Council also approved the homologous enhanced immunization of the new coronavirus inactivated vaccine of Shenzhen Kangtai Company and the Institute of Biology of the Medical Academy. Whether it is homologous enhancement or sequential strengthening, it needs to be implemented in people over 18 years of age who have completed the full vaccination for 6 months.
The research data shows that homologous enhanced immunization and sequential enhanced immunization can further improve the immunization effect, and people who hope to meet the vaccination conditions can take the initiative to vaccinate and vaccinate early, increase health and fuel epidemic prevention.
SUPPORTED BY WHO
Flexible cognate vaccines and heterologous vaccination schedules
Wang Huaqing, chief expert of the immunization program of the Chinese Center for Disease Control and Prevention, said that there are still many technical routes for global vaccination of new crown vaccines, and the virus is constantly changing. Based on the research evidence, sequential intensification of immunization has been initiated in the Americas, both in South and North America, as well as in Some countries in Europe and South-East Asia.
The World Health Organization supports flexible homologous vaccines and heterologous vaccination programmes. Of course, for countries considering heterologous vaccination regimens, the World Health Organization recommends follow-up vaccination with a new coronavirus vaccine with a different technical route from the first dose based on the background that heterologous vaccination and homologous vaccination have the same or higher immunogenicity or efficacy, as well as vaccine accessibility.
At present, the World Health Organization is also constantly collecting and accumulating more clinical trial evidence, constantly improving homologous and heterologous basic immunity and strengthening immunization strategies.
Sequential inoculation
There are special considerations
Wang Huaqing introduced that there are some special precautions for sequential vaccination.
About the objects of sequential immunization:
The first is people over the age of 18;
The second is to complete 2 doses of inactivated vaccination, and these 2 doses are the inactivated vaccine of the new crown virus of Sinopharm Zhongsheng Beijing Company, Beijing Kexing Company, and Sinopharm Zhongsheng Wuhan Company;
The third is to complete 2 doses of vaccination throughout the whole process, and the interval between vaccinations cannot be less than 6 months.
Fourth, there has been no enhanced immunization, that is, the 3rd injection has not been administered, so several conditions should be strictly grasped.
In addition, as with the precautions for receiving the new crown vaccine in the past, including understanding the relevant regulations of local vaccination before vaccination, because it is still the epidemic period, in this process, when everyone goes to the vaccination, they must do a good job of personal protection, including when they are vaccinated, they must truthfully reflect their health status to the vaccination doctor, and the vaccination doctor will judge whether there are contraindications or some delayed situations.
Finally, after vaccination, it is necessary to stay for 30 minutes, and when there is a suspected adverse reaction related to vaccination, if the duration is longer and the symptoms are more serious, one is to report to the vaccination unit, and the other is to seek medical treatment in time.
"Talking about the Omikejong mutant strain"
The mainland COVID-19 vaccine strengthens immunization
It reduces the retransmission ability of Omi kerong
Guo Yanhong, supervisor of the Medical Administration Bureau of the National Health Commission, introduced that through the epidemiological analysis of existing cases, the intergeneration spacing between cases of Omicron infection is on average 3 days, which is further shortened by about 4 days of the Derta variant, and the transmission capacity of the Omicron variant is about 2 times that of the Delta variant, and the transmission capacity is stronger.
Symptoms of Omiljung infection are atypical and the transmission process is more insidious. Case classification is mainly mild and ordinary, and the symptoms are relatively mild, and the imaging changes in patients are atypical.
As of January 20 this year, a total of 759 infected people were reported in Tianjin and Anyang, all of which were Omilon strains. There were only 4 severe cases in Tianjin, and there were no severe cases in the Anyang transmission chain, and the incidence of severe disease was only about 0.6%, which shows that the symptoms caused by Omi Kerong itself are relatively mild.
However, studies have found that within 6 months of completing immunization, the risk of pneumonia (ordinary type and above) in people infected with the new crown virus can be reduced by 60%. In close-knit populations, breakthrough infection rates of completed basic immunization and enhanced immunization were 22.6% and 6.0%, respectively. Boosting immunity can reduce the breakthrough infection rate of Aomi Kerong by more than 3 times compared with basic immunity.
These data all show that for the Omiljung strain, the mainland COVID-19 vaccine can reduce the risk of developing pneumonia, which in turn can reduce the incidence of severe illness and death. The enhanced immunization of our country's NEW CROWN vaccine has an inhibitory effect on the breakthrough infection of the Aumechroon strain, which can reduce the retransmission capacity of the Olmi kerong strain.
The mainland has deployed vaccine research and development units
Carried out vaccine research and development of the Omi kerong variant
Shao Yiming, a member of the expert group of the vaccine research and development special class, introduced that according to the real-world research that has been carried out in the mainland, the full vaccination of the new crown vaccine in the mainland can significantly reduce the risk of pneumonia and severe disease caused by the Omiclon variant, and strengthening immunity can not only reduce the risk of pneumonia and severe illness, but also reduce the breakthrough infection rate caused by the Aomi kerong variant to a certain extent. The so-called breakthrough infection is the new crown virus infection that appears after the whole process of vaccination.
On the other hand, in order to be prepared, the mainland has deployed vaccine research and development units to carry out vaccine research and development of the Aomi Kerong variant.
First, the inactivated vaccine research of the Aomi Kerong strain has been carried out, and the preclinical research has been completed, and the clinical trial declaration materials have been submitted to the Drug Evaluation Center for rapid progress;
Second, broad-spectrum or multivalent recombinant protein vaccine research has been carried out for the Omikejong strain, and those with faster progress have also submitted clinical trial declaration materials to the Drug Review Center on a rolling basis;
The third is to carry out the research and development of adenovirus vector vaccines and nucleic acid vaccines for the Aomi Kerong strain, and the animal efficacy and safety experiments that have progressed rapidly have been completed, and clinical trials are being prepared for declaration;
Fourth, the relevant institutions have completed the guiding principles for the research and development and evaluation of the vaccine of the mutant strain, and issued them to the vaccine research and development units point-to-point.
Text: Synthesized from Xinhua News Agency, People's Daily, CCTV News
Pictured: China Webcast
Guangzhou Daily New Flower City Editor Lin Chuanling